Andrew Saik - 28 May 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: Chief Financial Officer
Signature: /s/ Mutya Harsch, attorney-in-fact for Andrew Saik
Issuer symbol: VYNE
Transactions as of: 28 May 2021
Net transactions value: +$10,130
Form type: 4
Filing time: 02 Jun 2021, 16:31:40 UTC
Next filing: 22 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Award	$10,130	+3,017	+2.7%	$3.36	116,468	28 May 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period).

Content

These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period).